- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02378090
A Study to Determine the Causes and Identify Increases in Influenza-Like Illness (ILI) in Mexico
An Observational Study to Determine the Causes and Identify Increases in Influenza-Like Illness (ILI) in Mexico: The Mexican Emerging Infectious Disease Clinical Research Network (La Red)
Study Overview
Status
Detailed Description
The La Red Network clinical sites will enroll individuals presenting with ILI symptoms. A systematic sample will be chosen across all sites, with the goal of choosing 3 subjects who are outpatients and 3 subjects who are hospitalized every week at each site. It is recognized that, during seasons of low ILI activity, this enrollment goal may not be achieved. To be eligible for selection, subjects must be willing to sign informed consent, or provide informed consent/assent in the case of minors.
Subjects will be followed for a period of 28 days after enrollment to assess vital status. It is estimated that this study will enroll a maximum of 1872 subjects per year for an approximate 7488 subjects in the four years that the study proposes to enroll, depending upon the extent of ILI occurring during the period of this study.
Nasopharyngeal swabs, sputum samples, and blood samples will be obtained at enrollment. The nasopharyngeal swabs and, in adults > 18 years of age, portion of the blood for serum and peripheral blood mononuclear cells (PBMC) will be obtained for storage and shipped to the central repository located at the Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán for respiratory pathogen testing including real-time Polymerase Chain Reaction (PCR) and multiplex techniques.
All enrolled subjects will be assessed at enrollment, at 7 days (+3 days) and at 28 days (+/- 5 days) after enrollment to assess disease resolution and vital status.
The purpose of the study is to provide information regarding the pathogens causing ILI among patients seeking care at the La Red Network sites. The systematic collection of data over time will allow for the determination of seasonal patterns of different etiologic agents and the ability for early identification of the emergence of particular viruses, as well as the ability to identify changes in severity of disease signaled by an increase of severity, hospitalization and/or death attributable to a specific pathogen.
One important aspect of influenza infection is to the need to identify genetic factors associated with severity among patients who present with influenza and develop severe disease. Subjects will be given the option to opt out of the genetic testing by noting it on the informed consent form. This testing will be limited to studies related to respiratory viruses and influenza, and any study designed to use genetic testing. These studies will be submitted for review by the institutional review boards (IRBs) of the sites participating in the La Red Network.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
D. F.
-
Mexico City, D. F., Mexico
- Hospital General y de Alta Especialidad Manuel Gea Gonzalez
-
Mexico City, D. F., Mexico
- Hospital Infantil de Mexico Federico Gomez
-
Mexico City, D. F., Mexico
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
-
Mexico City, D. F., Mexico
- Instituto Nacional de Enfermedades Respiratorias
-
Mexico City, D. F., Mexico
- Instituto Nacional de Pediatría
-
-
Potosi
-
San Luis, Potosi, Mexico
- Hospital Central Dr. Ignacio Morones Prieto/ Universidad Autonoma de San Luis Potosi
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Signed informed consent by participant. In pediatric subjects, signed informed consent by the parent(s) or legal guardian(s) and, as required by the Institutional Ethics Committee (IEC), signed assent by participant.
An acute respiratory infection with:
- Measured fever of ≥ 38°C or history of fever;
- Cough; and
- Onset within the last 10 days.
Exclusion Criteria:
- Onset of ILI illness while hospitalized for any other cause to avoid enrollment of potential nosocomial infections (nosocomial).
- Subjects previously included in this study within the last 30 days of enrollment.
- Having been cared for in the hospital for a period >24 hours.
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Etiologic agents causing ILI and SARI among patients seeking medical care at participating sites in Mexico.
Time Frame: 4 years
|
Difference in the proportion of a determined isolated etiologic agent (or hospitalization) in the current 2 weeks (increases) in relation to the prior 8 weeks
|
4 years
|
Collaborators and Investigators
Collaborators
Investigators
- Study Chair: Arturo Galindo-Fraga, MD, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
- Study Chair: Daniel Noyola, MD, Hospital Central "Dr. Ignacio Morones Prieto"
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ILI-2014
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Respiratory Infections
-
Hôpital Universitaire SahloulCompleted
-
Wits Health Consortium (Pty) LtdFred Hutchinson Cancer Center; Janssen Vaccines & Prevention B.V.; National Institute... and other collaboratorsCompletedSARS (Severe Acute Respiratory Syndrome)South Africa
-
Washington University School of MedicineNational Institute of Allergy and Infectious Diseases (NIAID)Completed
-
Pulmoquine Therapeutics, IncRockefeller UniversityCompletedSevere Acute Respiratory Syndrome Coronavirus 2United States
-
University of Cape TownUniversity of KwaZuluUnknownSevere Acute Respiratory Syndrome Coronavirus 2South Africa
-
University of SaskatchewanGovernment of Canada; Vaccine Formulation Institute (VFI); Government of Saskatchewan and other collaboratorsCompletedSevere Acute Respiratory Syndrome Coronavirus 2Canada
-
University Hospital, Strasbourg, FranceCompletedSARS (Severe Acute Respiratory Syndrome)France
-
University of SaskatchewanGovernment of Canada; Vaccine Formulation Institute (VFI); Government of Saskatchewan and other collaboratorsActive, not recruiting
-
University of SaskatchewanGovernment of Canada; Government of SaskatchewanWithdrawnSevere Acute Respiratory Syndrome Coronavirus 2
-
University of WashingtonJohns Hopkins University; National Institute of Diabetes and Digestive and... and other collaboratorsActive, not recruitingCovid19 | Acute Renal Failure | Acute Renal Injury | Acute Kidney Failure | Kidney Failure, Acute | Renal Insufficiency, Acute | Acute Renal Insufficiency | Sars-CoV-2 Infection | Acute Kidney Insufficiency | Renal Failure, Acute | Kidney Insufficiency, AcuteUnited States